Point72 Asset Management
STRO icon

Point72 Asset Management’s Sutro Biopharma STRO Stock Holding History

Point72 Asset Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.2M Buy
692,111
+513,023
+286% +$9.27M 0.02% 887
2025
Q4 		$2.07M Buy
+179,088
New +$1.7M ﹤0.01% 2449
2025
Q1 		– Sell
-219,754
Closed -$4.04M – 2514
2024
Q4 		$4.04M Sell
219,754
-79,991
-27% -$2.44M 0.01% 1020
2024
Q3 		$10.4M Sell
299,745
-145,018
-33% -$5.68M 0.03% 635
2024
Q2 		$13M Buy
444,763
+418,693
+1,606% +$16.6M 0.03% 520
2024
Q1 		$1.47M Sell
26,070
-2,500
-9% -$110K ﹤0.01% 1364
2023
Q4 		$1.23M Sell
28,570
-24,745
-46% -$785K ﹤0.01% 1345
2023
Q3 		$1.85M Buy
53,315
+32,415
+155% +$1.41M 0.01% 1151
2023
Q2 		$972K Buy
+20,900
New +$1.04M ﹤0.01% 1147
2023
Q1 		– Sell
-79,060
Closed -$6.39M – 2529
2022
Q4 		$6.39M Buy
79,060
+7,960
+11% +$553K 0.02% 685
2022
Q3 		$3.95M Buy
+71,100
New +$4.21M 0.02% 786
2021
Q4 		– Sell
-37,500
Closed -$7.08M – 1291
2021
Q3 		$7.08M Sell
37,500
-76,160
-67% -$14.5M 0.03% 578
2021
Q2 		$21.1M Buy
113,660
+17,840
+19% +$3.49M 0.09% 274
2021
Q1 		$21.8M Sell
95,820
-45,111
-32% -$10.7M 0.1% 244
2020
Q4 		$30.6M Buy
140,931
+39,881
+39% +$6.6M 0.15% 189
2020
Q3 		$10.2M Buy
101,050
+41,050
+68% +$3.88M 0.05% 402
2020
Q2 		$4.66M Buy
+60,000
New +$5.76M 0.03% 495
2019
Q3 		– Sell
-32,238
Closed -$3.67M – 1450
2019
Q2 		$3.67M Buy
+32,238
New +$3.55M 0.02% 570

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Point72 Asset Management's STRO Position: Q1 2026 in Review

Point72 Asset Management increased its Sutro Biopharma (STRO) stake by 286% in Q1 2026, buying an estimated $9.27M and bringing the position to 692,111 shares worth $17.2M. The position accounts for 0.02% of the portfolio, ranked #887.

Point72 Asset Management first reported a position in STRO in Q2 2019 and has held it in 18 quarters since. The position peaked at $30.6M in Q4 2020. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Point72 Asset Management held 692,111 shares of Sutro Biopharma worth $17.2M as of Q1 2026.
  • Point72 Asset Management bought 513,023 Sutro Biopharma shares in Q1 2026, an estimated $9.27M.
  • Sutro Biopharma made up 0.02% of Point72 Asset Management's portfolio in Q1 2026, its #887 holding.
  • Point72 Asset Management first reported a position in Sutro Biopharma in Q2 2019 and has held it in 18 quarters since.
  • Point72 Asset Management's Sutro Biopharma position peaked at $30.6M in Q4 2020.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.